UNSPSC 51112103: Alitretinoin

This classification denotes a retinoic acid agent with the molecular formula C20H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1UA8E65KDZ, chemically known as 2,4,6,8-nonatetraenoic acid, 3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-, (all-e)- but more generally known as alitretinoin, which bears US NIH Compound Identifier 444795. European Medicines Agency schedules Alitretinoin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00344MIG.

UNSPSC 51112103 Alitretinoin is a Commodity code that represents a specific pharmaceutical active ingredient used in dermatological treatment. State and local governments procure alitretinoin primarily through pharmacy benefit programs and Medicaid formularies to serve eligible populations, typically acquired via pharmaceutical wholesalers, group purchasing organizations, or direct manufacturer relationships as part of broader prescription drug procurement activities. The issuing bodies soliciting under this code include state health and human services agencies that manage pharmacy benefits for Medicaid beneficiaries, state employees, and retirees, as well as regional health authorities and public health programs that dispense pharmaceuticals.

The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program designed to establish direct contracting relationships between the state's pharmacy benefit program and pharmaceutical manufacturers to improve prescription fulfillment and manage costs. The RFI requested information from vendors on their experience with direct contracting for self-insured employers and health plans, flexibility to negotiate contracts based on net pricing models without rebates, and capability to implement value-based agreements. Texas represents the primary recent activity under this code; the source does not identify opportunities in other states or jurisdictions during the recent period.